ACADIA Historical Cash Flow
| ACAD Stock | USD 17.07 0.12 0.70% |
Analysis of ACADIA Pharmaceuticals cash flow over time is an excellent tool to project ACADIA Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 496.9 K or Net Income of 237.8 M as it is a great indicator of ACADIA Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining ACADIA Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ACADIA Pharmaceuticals is a good buy for the upcoming year.
ACADIA |
About ACADIA Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in ACADIA balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which ACADIA's non-liquid assets can be easily converted into cash.
ACADIA Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from ACADIA Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' End Period Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Change In Cash is expected to grow to about 140.6 M, whereas Other Non Cash Items is projected to grow to (134.4 M).
| 2024 | 2025 (projected) | Sale Purchase Of Stock | 20.9M | 19.8M | Stock Based Compensation | 67.0M | 63.7M |
ACADIA Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
ACADIA Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ACADIA Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Working Capital | 11.0M | (24.8M) | 38.0M | 18.1M | 4.2M | 3.8M | |
| Other Non Cash Items | 44.3M | 75K | (6.3M) | (12.1M) | (141.4M) | (134.4M) | |
| Capital Expenditures | 1.1M | 7.6M | 1.1M | 40.1M | 523K | 496.9K | |
| Net Income | (281.6M) | (167.9M) | (216.0M) | (61.3M) | 226.5M | 237.8M | |
| End Period Cash Flow | 331.8M | 153.2M | 120.6M | 188.7M | 328.4M | 344.8M | |
| Change In Cash | 137.3M | (178.6M) | (32.6M) | 73.8M | 133.9M | 140.6M | |
| Free Cash Flow | (143.8M) | (126.8M) | (114.0M) | (23.3M) | 157.2M | 165.1M | |
| Begin Period Cash Flow | 194.5M | 331.8M | 153.2M | 114.8M | 194.4M | 204.1M | |
| Total Cashflows From Investing Activities | (165.8M) | 192.5M | (71.1M) | 73.2M | 65.9M | 69.2M | |
| Other Cashflows From Financing Activities | 192.5M | (71.1M) | 73.2M | 32.0M | 36.8M | 71.1M | |
| Depreciation | 2.9M | 3.3M | 2.0M | 5.6M | 5.7M | 5.9M | |
| Total Cash From Operating Activities | (136.2M) | (125.7M) | (114.0M) | 16.7M | 157.7M | 165.6M | |
| Total Cash From Financing Activities | 81.0M | 18.2M | 8.2M | 25.1M | 6.8M | 6.5M | |
| Change To Liabilities | 12.0M | 31.2M | (8.2M) | 5.9M | 6.8M | 5.7M | |
| Stock Based Compensation | 84.4M | 63.6M | 68.2M | 66.4M | 67.0M | 63.7M | |
| Sale Purchase Of Stock | 306.6M | 371.8M | 81.0M | 18.2M | 20.9M | 19.8M | |
| Change To Inventory | (3.3M) | (4.2M) | 2.4M | (28.8M) | (49.6M) | (47.1M) | |
| Investments | 200.1M | (70.0M) | 73.2M | 32.0M | (30.5M) | (32.1M) | |
| Cash And Cash Equivalents Changes | 67.7M | 54.9M | 137.3M | (178.6M) | (160.7M) | (152.7M) | |
| Cash Flows Other Operating | (12.5M) | 3.5M | (4.4M) | 2.7M | 2.4M | 2.5M | |
| Change To Account Receivables | (12.5M) | (16.1M) | 2.2M | (39.3M) | (472K) | (495.6K) | |
| Other Cashflows From Investing Activities | 200.1M | (70.0M) | 73.2M | 32.0M | 146.5M | 153.8M | |
| Change To Netincome | 81.3M | 130.0M | 61.3M | 61.9M | 71.2M | 56.3M | |
| Change Receivables | (9.4M) | (10.1M) | (12.4M) | (15.1M) | (13.6M) | (12.9M) | |
| Change To Operating Activities | 11.1M | 25.6M | (2.9M) | 27.5M | 31.7M | 33.2M | |
| Issuance Of Capital Stock | 81.0M | 18.2M | 8.2M | 25.1M | 6.8M | 6.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.133 | Earnings Share 1.36 | Revenue Per Share | Quarterly Revenue Growth 0.124 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.